$EVO

Evotec SE, a German drug discovery specialist, continues to attract attention for its refining pipeline and global footprint, particularly among biotech-focused investors. The company operates as a global research and development platform for pharmaceutical and biotech groups, leveraging a diversified partnering model that includes fee-for-service contracts, integrated alliances, and potential milestone and royalty income. This approach aims to spread scientific and financial risk while providing exposure to the biotechnology innovation landscape for US and international investors.